Can J Cardiol. 2025 Dec 16:S0828-282X(25)01575-2. doi: 10.1016/j.cjca.2025.12.015. Online ahead of print.
ABSTRACT
With an aging population, the prevalence of valvular heart disease (VHD) has risen steadily and is expected to continue increasing in the coming decades. In parallel, the remarkable development of transcatheter therapies has dramatically expanded both the therapeutic landscape and the number of patients eligible for curative interventions. Together, these trends have created a growing financial, societal, and logistical burden on healthcare systems worldwide. Despite technological breakthroughs, major challenges persist. Many patients with VHD remain undiagnosed, are referred late in the disease course, and ultimately receive suboptimal treatment. Unlike atherosclerosis or heart failure, where medical therapies have led to major clinical advances, there is currently no effective medical therapy to slow or prevent degenerative VHD progression. Healthcare systems face significant constraints, including shortages of healthcare providers, limited access to primary care, restricted availability of diagnostic testing and cardiology services. These challenges are particularly pronounced particularly in publicly funded systems such as Canada, where direct specialist access is limited, and hospital capacity is insufficient. These challenges are unevenly distributed: individuals with low socioeconomic status or those living in rural or underserved areas bear the greatest burden. Moreover, structured and coordinated healthcare pathways for valve disease remain lacking. Addressing these challenges requires opening up the future of valve disease: expanding early detection beyond hospital walls, integrating digital and community-based care, fostering big data and innovation networks, and accelerating the development of medical therapies and personalized medicine approaches through multidisciplinary collaboration that can truly transform patient outcomes.
PMID:41412281 | DOI:10.1016/j.cjca.2025.12.015